What PG.600 Treats: Main Uses and Benefits

PG.600 is commonly used in conditions characterized by periods of heightened symptoms associated with the female swine reproductive cycle.

Inducing Estrus in Non-Cycling Sows

This medication is commonly used in conditions that involve systemic imbalance associated with the absence of reproductive cycling (anoestrus), which is frequently observed in mature weaned sows that are experiencing a functional delay. The intervention is relevant for easing symptoms related to the absence of expected reproductive activity. It provides support that helps ease the overall symptom burden of physiological imbalance.

Addressing Delayed Reproductive Maturation in Gilts

PG.600 is also applied to address delayed reproductive maturation in prepuberal gilts, which are young female swine that have not yet started their first estrus despite reaching the expected age and weight. This application is used when short-term symptomatic assistance is needed to achieve the onset of the reproductive cycle and supports patients during episodes of heightened discomfort.

Facilitating Estrus Synchronization for Management

A relevant therapeutic use in commercial settings is its role in estrus synchronization, helping to manage symptom clusters that may become disruptive by supporting a predictable time point for breeding. This application contributes to improved comfort by supporting a predictable breeding schedule, which is commonly used for managing symptomatic relief in situations requiring short-term symptomatic support.

Context: Managing Functional Quiescence PG.600 supports the patient during episodes of heightened discomfort by addressing the physiological state of ovarian inactivity in breeding female swine, and assists with maintaining functional stability in settings where episodic manifestations are present.

Regulatory References

1. NIH DailyMed label information

PG.600 is a veterinary medicinal product indicated strictly for use in pigs (swine) to induce estrus.

Official Eligibility

Eligible Populations:

• Prepuberal Gilts: Must be healthy, non-cycling, over five and one-half months of age, and weighing at least 85 kg (187 lb.).
• Sows at Weaning: Must be healthy and experiencing a delayed return to estrus.

Age-Related Rule: Gilts that are less than the specified age or weight may not be mature enough to sustain a normal pregnancy to full term after treatment.

Contraindications and Restrictions

Populations for Whom Use is Prohibited or Not Indicated:

• Humans: The product is labeled FOR ANIMAL USE ONLY.
• Gilts that have already reached puberty (begun to cycle): Treatment will not induce estrus in these animals.
• Pregnant sows or gilts: Use during pregnancy is not indicated.
• Sows returning to estrus normally (three to seven days after weaning): Treatment will not induce estrus.
• Sows or gilts where corpora lutea are present on the ovary at the time of administration, as the animal will fail to respond.

Regulatory Context: The regulatory documentation defines PG.600 as a restricted-use tool for swine production, allowing its use only in specific, non-cycling or delayed-cycling females within the target species.

Interactions with other medicines and products

Official regulatory information for PG.600 establishes a minimal interaction profile with other medicinal products. The product's Summary of Product Characteristics, reviewed by regulatory bodies such as the European Medicines Agency (EMA) and the UK Veterinary Medicines Directorate (VMD), explicitly states that no interactions are known with other medicinal substances or other forms of interaction.

This official finding indicates that the regulatory documents do not specify any interactions that would alter the systemic exposure of PG.600 or co-administered drugs. Consequently, there are no listed substances or drug classes documented to cause pharmacokinetic (e.g., enzyme-mediated) or pharmacodynamic effects (e.g., additive effects) when used concurrently.

Administration and Preparation Restriction

While drug-drug interactions are not documented, the regulatory labeling does include a critical administrative constraint classified as a major incompatibility related to preparation. This procedural restriction mandates that the lyophilized powder and solvent for PG.600 must not be mixed with any other veterinary medicinal product except for the solvent provided by the manufacturer for its reconstitution. This rule is a formal constraint concerning the product's preparation before injection. No mandatory timing rules for separating administration with other non-incompatible medicines are specified.

No interaction is documented with food, alcohol, herbal products, or supplements in the official regulatory product information.

PG.600 is a modulator that primarily affects the Wnt pathway in bone tissue. It operates by stabilizing the intracellular beta-catenin complex, which is a key component of canonical Wnt signaling. This stabilization leads to an increase in beta-catenin-mediated transcriptional activity within osteoblasts. This enhanced signaling modulates the expression of genes essential for bone turnover. Specifically, this cascade results in a decrease in the ratio of Receptor Activator of NF-kappaB Ligand (RANKL) relative to Osteoprotegerin (OPG). Furthermore, PG.600's action reduces the commitment and differentiation of osteoclast precursors. The collective effect of these molecular interactions is the modulation of the bone remodeling unit by altering the balance between bone formation and bone resorption processes.

The administration of PG.600 follows a standardized, single-use protocol. The medicine is supplied as a lyophilized powder that must be reconstituted using the supplied sterile solvent immediately prior to administration; the resulting solution is not approved for storage. The official dose is a fixed, single injection containing 400 IU of Serum Gonadotropin and 200 IU of Chorionic Gonadotropin. This combined dose is delivered in a volume of 5 mL of the prepared solution.

The approved route of administration is primarily subcutaneous (under the skin), or intramuscular (into the muscle). In either case, the injection is directed into the neck area, behind the ear. The schedule is a one-time event designed to provide an acute hormonal stimulus, with no required maintenance or follow-up doses. The timing is governed by the animal's reproductive stage. For prepuberal gilts, the product is indicated only when the animal meets a minimum weight of approximately 85 kg and is at least 5.5 months of age. For weaned sows experiencing delayed return to estrus, the single injection is scheduled at the time of weaning or shortly thereafter. This precise, non-cyclical administration pattern defines the entirety of the usage protocol.

Research Evidence / Overview of Studies for PG.600

Evidence for Use in Delayed Reproductive Maturation in Gilts

Research exploring the use of PG.600 in female swine focuses in part on prepuberal gilts, which are young animals that have not yet started their reproductive cycle despite reaching the expected age and size. Studies conducted during periods of increased symptom activity, such as the delay in reproductive maturation, primarily consist of short-term Randomized Controlled Trials (RCTs). These RCTs research examined populations of generally healthy gilts and were applied in studies monitoring estrus activity (heat). The main outcome was the proportion of gilts that exhibited estrus (heat) observed during the study period within a defined short-term interval.

The studies focused on outcomes related to systemic or functional imbalance. Studies reported measurements where the percentage of gilts exhibiting estrus differed when compared between treated and control groups. The research also monitored the time interval from administration until the onset of estrus, with data showing patterns related to measurements of the time-to-estrus interval. Evidence is limited for long-term outcomes; research exploring subsequent measures such as overall farrowing rate and litter size found that long-term effects are not fully established regarding improvements in final reproductive success.

Evidence for Use in Anoestrus or Delayed Return to Estrus in Sows

Research also explored PG.600 in weaned sows that experience a temporary physiological imbalance marked by a delay in the return of estrus (anoestrus). This research primarily involved Randomized Controlled Trials (RCTs) and controlled field trials. These studies were designed to monitor the proportion of weaned sows that exhibited estrus during a short, critical period, as well as the weaning-to-estrus interval (WEI).

Studies monitored outcomes reflecting daily functioning. Research reported measurements where the percentage of sows exhibiting estrus differed when compared between the treated and control groups within the short post-weaning window. Data also showed patterns related to measurements of the weaning-to-estrus interval (WEI). Findings for subsequent measures like litter size and farrowing rate were mixed, and data for these long-term outcomes remain insufficient to draw firm conclusions regarding a consistent influence or improvement.

What Research Gaps and Uncertainties Exist

Findings from regulatory summaries highlight several areas where certainty remains low. The primary research gap lies in long-term reproductive performance. While research explored the timing and estrus activity of the reproductive cycle, research does not definitively establish that this initial intervention leads to a consistent, improved outcome in the subsequent litter size or farrowing rate. Furthermore, external factors such as environmental conditions or management practices may contribute to the overall measured outcome, and follow-up durations were limited for understanding effects over multiple subsequent breeding cycles.

Key Studies & References PG 600 (chorionic gonadotropin; serum gonadotrophin) Injectable - DailyMed Label Information

Common questions about PG.600 (FAQ)

Q: What does the '.600' part of the drug name refer to?

A: The number 600 refers to the total number of International Units (IU) of gonadotropins in a single, fixed dose. Official product information states that this total is composed of 400 IU of Serum Gonadotropin and 200 IU of Chorionic Gonadotropin.

Q: Is it normal to see signs of heat a few days after giving the injection?

A: Official regulatory documents indicate that the combination of hormones in PG.600 is designed to stimulate estrus (heat). The expected timeframe for this response, based on product data, is typically within three to seven days following the single injection.

Q: Is PG.600 used for other animals besides the primary labeled species?

A: The product is officially labeled and indicated strictly for use in pigs (swine). This includes prepuberal gilts and weaned sows. The regulatory authorities have not approved its use in other animal species.

Q: Can PG.600 be used to treat fertility problems caused by environmental stress?

A: The official indication is for use in weaned sows experiencing a delayed return to estrus. While the product information notes that this delay often occurs during periods of adverse environmental conditions, the medicine addresses the resulting hormonal delay rather than the underlying stress itself.

Q: Does PG.600 work if the recipient already has a normal reproductive cycle?

A: No, the official restrictions state that PG.600 is not indicated for use in females that are already cycling normally. This includes gilts that have already reached puberty and sows that are returning to estrus normally within three to seven days after weaning.

Q: How long does the effect of PG.600 typically last in the body?

A: Studies on pharmacokinetics show that both active ingredients are rapidly absorbed after injection, reaching their peak concentration within about 8 hours. The hormones are then processed by the body, with pharmacokinetic data indicating an elimination half-life of approximately 27 to 36 hours for the active components.

Q: Is it true that a high dose of PG.600 can sometimes have a negative effect on pregnancy rates?

A: The regulatory label approves a fixed, single injection containing 400 IU of Serum Gonadotropin and 200 IU of Chorionic Gonadotropin for its indicated use. The effects of administering doses higher than this approved amount are not addressed in the regulatory product information.

Q: Does PG.600 have a withdrawal period before meat can be consumed?

A: Yes, the official regulatory documents specify a withdrawal period to ensure food safety. The withdrawal period for meat and offal from treated animals is Zero days.

Q: Are there any long-term health concerns noted from using PG.600?

A: The regulatory safety profile is defined primarily by the potential for rare, acute hypersensitivity (allergic) reactions, such as anaphylactic shock. Long-term non-reproductive health effects following the single-dose use are not addressed in the official product information.

Q: What is the function of the hCG component in PG.600's mechanism?

A: The Chorionic Gonadotropin (hCG) component is a hormone that acts similarly to the body’s Luteinizing Hormone (LH). This action is responsible for triggering the final maturation of the follicles and stimulating ovulation.

Q: How does the PMSG component contribute to the drug's effect?

A: The Serum Gonadotrophin (PMSG or eCG) component acts like the body's Follicle-Stimulating Hormone (FSH). Its contribution is to stimulate and promote the initial growth and development of ovarian follicles.

Q: Why might a recipient fail to show a response after receiving PG.600?

A: Official precautions state that a recipient may fail to show the desired reproductive response if structures known as corpora lutea (CL) are present on the ovary at the time the injection is given.

Q: Is there a risk of hormonal modulation in humans from accidental contact with the product?

A: The product contains biologically derived reproductive hormones. In line with general safety for such products, accidental contact or self-injection has the potential to cause hormonal modulation in humans.

Q: Are there studies comparing PG.600 to no treatment (control groups)?

A: Yes, the research used to support the product's efficacy primarily consists of short-term Randomized Controlled Trials (RCTs). These studies were designed to compare the reproductive response of treated groups against control groups that received no treatment.

Q: Does using PG.600 require any specific pre-screening or testing?

A: While no specific laboratory tests are mandated by the regulatory documents, the recipient must be confirmed as healthy and meet minimum age and weight requirements to be considered eligible for the treatment.

Q: Is it normal to see an increase in follicle count after administering PG.600?

A: This is consistent with the drug’s intended mechanism of action. The Serum Gonadotrophin component mimics FSH, which stimulates the growth and development of ovarian follicles.

Q: What is the maximum number of days post-treatment that a positive response is expected?

A: The product is designed to provide an acute hormonal stimulus. Official documents indicate that a positive estrus response is expected within a short-term interval of three to seven days after the single administration.

Q: Does PG.600 help recipients that have a delayed return to heat due to poor appetite during lactation?

A: The product is indicated for sows experiencing a delayed return to estrus after weaning. While poor appetite during lactation is one factor that can lead to this delay, the product’s function is to address the resulting hormonal imbalance.

Q: Is there a possibility of developing antibodies to the hormones in PG.600?

A: Since the active ingredients are biologically derived glycoprotein hormones (proteins), the safety profile accounts for the potential for immunological reactions. This includes rare hypersensitivity events due to the protein nature of the components.

Q: What precautions should be taken if there is accidental self-injection?

A: If accidental self-injection occurs, the user should immediately wash the area thoroughly with soap and water. Regulatory precautions mandate seeking immediate medical advice following self-injection, and the user should take the product packaging or leaflet to aid the medical assessment.

Q: Why might PG.600 be less effective after later litters?

A: Product information notes that the effectiveness of PG.600 has not been established after later litters. This is often because delayed return to estrus is a more common issue after a sow's first litter.

Q: How quickly does the active substance in PG.600 get absorbed after injection?

A: Pharmacokinetic studies indicate that both active substances are rapidly absorbed into the bloodstream. They reach their maximum concentrations approximately 8 hours after the injection is administered.

Q: Why might a recipient experience a smaller than normal litter after treatment in adverse conditions?

A: Regulatory cautions state that sows mated under conditions that are already associated with a delayed return to estrus—such as adverse environmental conditions—may subsequently farrow smaller than normal litters.

Q: What is the difference in use of PG.600 for prepubertal vs. post-weaned recipients?

A: The primary difference lies in the reproductive status of the recipient. For prepuberal gilts, the medicine is used to induce the very first estrus. For weaned sows, it is used specifically to induce estrus only when the return to heat is delayed.

Q: Does the time of year (e.g., summer) affect the efficacy of PG.600?

A: Regulatory documents indicate that delayed return to estrus is often observed during periods of adverse environmental conditions. This suggests that external factors, including the time of year, may affect the overall outcomes of breeding programs where PG.600 is used.

Q: What is the common misunderstanding about PG.600 and synchronization?

A: The product is correctly indicated for the induction and synchronization of estrus (heat). A common misunderstanding is that it will work for any female; however, the regulatory label strictly limits its use to those that are not actively cycling or have a delayed return to estrus.

Official Storage and Disposal Requirements

PG 600 must be stored strictly according to regulatory mandates to preserve its stability as a biological injectable. The unreconstituted product (powder and solvent) requires refrigerated storage between 2 C and 8 C and must be protected from light to maintain its shelf life. The storage container should be kept out of the sight and reach of children.

After the powder is dissolved, the reconstituted solution has a very limited stability period. It must be used within 24 hours when kept under refrigeration; any unused solution remaining after this time must be discarded.

Disposal instructions prohibit discarding the unused medicinal product or waste materials via wastewater or household waste. Disposal must be managed through official take-back schemes or national collection systems.